Anti-PD-1 Antibody Framework Region Segmentation for High Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents to modulate the activity of immunoinhibitory proteins like PD-1, which are crucial for regulating immune responses and are often exploited by cancer cells for immune evasion.
Innovation Solution
Development of high-affinity, specific antibody molecules that bind to PD-1, inhibiting its interaction with ligands like PD-L1 and PD-L2, thereby activating the immune system and potentially treating cancer and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-affinity antibody molecules are developed to bind PD-1, then the ability to inhibit PD-1-associated activities is improved, but the complexity of antibody development and manufacturing increases
Solution Approach 1:
The patent segments the antibody structure into distinct framework regions (FW1, FW2, FW3, FW4) and complementarity-determining regions (CDRs), allowing independent optimization of each segment. This enables systematic improvement of binding affinity through targeted modifications of specific framework regions without redesigning the entire antibody molecule.
Solution Approach 2:
The patent systematically varies amino acid sequences in framework regions to optimize binding parameters. By changing specific residues in FW1, FW2, FW3, or FW4, the antibody achieves enhanced affinity for PD-1 while maintaining structural integrity and manufacturability.
2Reliability
If specific antibody molecules are designed to inhibit PD-1 interaction with ligands, then the effectiveness of immune activation is improved, but the precision required in epitope targeting increases
Solution Approach 1:
The patent applies local quality by concentrating binding specificity in the CDR regions while using framework regions for structural support. This allows the antibody to achieve high specificity for PD-1 through localized interactions in the CDRs, reducing the need for precision across the entire antibody structure.
Solution Approach 2:
The framework regions act as intermediaries that position and orient the CDRs for optimal PD-1 binding. This intermediary structure facilitates specific epitope recognition while simplifying the manufacturing requirements by providing a stable, reproducible framework.
3Duration of action of stationary object
If novel framework region combinations are used to enhance antibody stability, then the durability of immune response is improved, but the difficulty of antibody engineering increases
Solution Approach 1:
The patent creates universal framework region combinations that can be paired with various CDR sequences to generate multiple antibodies with enhanced stability. These standardized framework modules (FW1, FW2, FW3, FW4) serve multiple functions: structural support, stability enhancement, and manufacturability improvement, reducing engineering complexity.
Solution Approach 2:
The patent performs preliminary optimization of framework regions before final antibody assembly. By pre-characterizing stable framework combinations and their pairing compatibility with CDRs, the engineering process is simplified, and durable immune responses are achieved through predetermined stable structures.
Data Source
AI summary
Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent, and/or diagnose cancerous or infectious conditions and disorders.